Richard Mbi Beteck

Prof. Richard Mbi Beteck

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2022 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
PDPhelelisiwe S. Dube
Phelelisiwe S. Dube
LLLesetja J. Legoabe
Lesetja J. Legoabe
RBRichard Mbi Beteck
Richard Mbi Beteck

30 August 2014 in Malaria Journal
Verified
Journal Article
Open access
PDF file
RBRichard Mbi Beteck
Richard Mbi Beteck
FSFrans Smit
Frans Smit
Richard K. HaynesRichard K. Haynes
Richard K. Haynes
DNDavid N'da
David N'da
Available anti-malarial tools have over the ten-year period prior to 2012 dramatically reduced the number of fatalities due to malaria from one million to less than six-hundred and thirty thousand. Although fewer people now die from malaria, emerging resistance to the first-line anti-malarial drugs, namely artemisinins in combination with quinolines and arylmethanols, necessitates the urgent development of new anti-malarial drugs to curb the disease. The quinolones are a promising class of compounds, with some demonstrating potent in vitro activity against the malaria parasite. This review summarizes the progress made in the development of potential anti-malarial quinolones since 2008. The efficacy of these compounds against both asexual blood stages and other stages of the malaria parasite, the nature of putative targets, and a comparison of these properties with anti-malarial drugs currently in clinical use, are discussed.

1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
OPOm Prakash Singh Patel
Om Prakash Singh Patel
OJOmobolanle Janet Jesumoroti
Omobolanle Janet Jesumoroti
LLLesetja J. Legoabe
Lesetja J. Legoabe
RBRichard Mbi Beteck
Richard Mbi Beteck

13 May 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Klaudia AngulaKlaudia Angula
Klaudia Angula
LLLesetja J. Legoabe
Lesetja J. Legoabe
RBRichard Mbi Beteck
Richard Mbi Beteck
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a curable airborne disease currently treated using a drug regimen consisting of four drugs. Global TB control has been a persistent challenge for many decades due to the emergence of drug-resistant Mtb strains. The duration and complexity of TB treatment are the main issues leading to treatment failures. Other challenges faced by currently deployed TB regimens include drug-drug interactions, miss-matched pharmacokinetics parameters of drugs in a regimen, and lack of activity against slow replicating sub-population. These challenges underpin the continuous search for novel TB drugs and treatment regimens. This review summarizes new TB drugs/drug candidates under development with emphasis on their chemical classes, biological targets, mode of resistance generation, and pharmacokinetic properties. As effective TB treatment requires a combination of drugs, the issue of drug-drug interaction is, therefore, of great concern; herein, we have compiled drug-drug interaction reports, as well as efficacy reports for drug combinations studies involving antitubercular agents in clinical development.

11 January 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
RBRichard Mbi Beteck
Richard Mbi Beteck
RSRonnett Seldon
Ronnett Seldon
AJAudrey Jordaan
Audrey Jordaan
DWDigby Warner
Digby Warner
HHHeinrich C. Hoppe
Heinrich C. Hoppe
SKSetshaba David Khanye
Setshaba David Khanye
Herein, we propose novel quinolones incorporating an INH moiety as potential drug templates against TB. The quinolone-based compounds bearing an INH moiety attached via a hydrazide–hydrazone bond were synthesised and evaluated against Mycobacterium tuberculosis H37Rv (MTB). The compounds were also evaluated for cytotoxicity against HeLa cell lines. These compounds showed significant activity (MIC90) against MTB in the range of 0.2–8 μM without any cytotoxic effects. Compounds 10 (MIC90; 0.9 μM), 11 (MIC90; 0.2 μM), 12 (MIC90; 0.8 μM) and compound 15 (MIC90; 0.8 μM), the most active compounds in this series, demonstrate activities on par with INH and superior to those reported for the fluoroquinolones. The SAR analysis suggests that the nature of substituents at positions −1 and −3 of the quinolone nucleus influences anti-MTB activity. Aqueous solubility evaluation and in vitro metabolic stability of compound 12 highlights favourable drug-like properties for this compound class.

2 October 2018 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
RBRichard Mbi Beteck
Richard Mbi Beteck
RSRonnett Seldon
Ronnett Seldon
DCDina Coertzen
Dina Coertzen
MWMariëtte E. van der Watt
Mariëtte E. van der Watt
JRJanette Reader
Janette Reader
Richard K. HaynesRichard K. Haynes
Richard K. Haynes
The quinolone decoquinate is coadministered with feed for treatment of parasites which cause coccidiosis in poultry. However, from a drug-development perspective, the biological activity is often not adequately exploited due to poor physicochemical properties. Here we convert decoquinate into N-alkyl quinolone amides that, in contrast to decoquinate, are active against the tuberculosis bacterium with MIC90 values ranging from 1.4 to 3.64 µM, and quinoline O-carbamates active against apicomplexan parasites that cause malaria, toxoplasmosis, and neosporosis with IC50 values of 0.32–1.5 nM for the best derivative. Uniquely for the TB-active amides, disruption of cell wall homoeostasis is identified as one target. With IC50 values against fetal lung fibroblast cells of 40 to >100 μM, the derivatives are selective for the pathogens. Structures of the most active derivatives are determined by NMR spectroscopy and X-ray crystallography. Analogues lacking the decyl side chain of decoquinate are inactive.